Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability, and Pharmacokinetics of Intravenous NTS-104 TRIS in Healthy Adults
NCT05547438Phase 1Terminated
- Sponsor
- NeuroTrauma Sciences
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Prodrugs/Conditional Activator Small Molecules, Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised trial of NTS-104 TRIS in ischemic stroke (2 arms), sponsored by NeuroTrauma Sciences. Primary endpoints: Adverse Events and Serious Adverse Events, Change from Baseline in Physical Examination and 3 more. Started May 2023; status: terminated.
02
Drugs
NTS-104 TRIS
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT05547438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05547438.